Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
The AAPS Journal|September 9, 2005
A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse dataHui-May Chu, Ene I EtteEpilepsy Research|September 29, 2019
Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndromeDwain Tolbert, Hui-May Chu, Ene I EttePharmaceutical Research|April 23, 2005
Data supplementation: a pharmacokinetic/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surfaceEne I Ette, Hui-May Chu, Christopher J GodfreyJournal of Clinical Pharmacology|July 4, 2015
An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokineticsDwain Tolbert, Ihor Bekersky, Hui-May Chu, et al.Journal of Clinical Pharmacology|July 31, 2015
Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactionsDwain Tolbert, Ihor Bekersky, Hui-May Chu, et al.Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.Neurology|September 1, 2023
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy BodiesJohn J Alam, Paul Maruff, Susan R Doctrow, et al.Annals of Clinical and Translational Neurology|April 25, 2018
An exploratory clinical study of p38α kinase inhibition in Alzheimer's diseasePhilip Scheltens, Niels Prins, Adriaan Lammertsma, et al.Hepatology (Baltimore, Md.)|September 20, 2007
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CNicole Forestier, Hendrik W Reesink, Christine J Weegink, et al.Gastroenterology|May 9, 2007
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirChristoph Sarrazin, Tara L Kieffer, Doug Bartels, et al.Pageof 2